The partnership reflects Abbott and Nordisk’s commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.
New Delhi: Healthcare provider, Abbott and Novo Nordisk recently announced a non-exclusive partnership with Novo Nordisk that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system).
Abbott’s FreeStyle Libre system reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for routine finger pricks. Abbott’s FreeStyle LibreLink app enables users to capture and view their real-time glucose levels, their eight-hour glucose history, and how their glucose is currently changing on their smartphone.
Libre View is a secure cloud-based diabetes management system that gives people with diabetes and healthcare professionals clear, easy-to-understand reports from major glucose monitoring devices – including the FreeStyle Libre system.
The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.
The company stated that integrating these two products will enable healthcare professionals, caregivers and people with diabetes to view glucose and insulin data together to help them make more informed treatment decisions and to have a more meaningful and productive conversation about health outcomes.
“Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,” said Anders Dyhr Toft, corporate vice president, Commercial Innovation, Novo Nordisk.
“Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient′s individual diabetes management and can help people with diabetes feel more confident in their treatment,” Toft added.
Senior vice president, Diabetes Care, Abbott, Jared Watkin said, “It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes.”
“Diabetes is a time-intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life,” he added.